Gastric Cancer: A Review of Risk Factors and New Insights into Treatment

Review by Prof. Hany Dabbous (Egypt)

Study Summary 

Gastric cancer (GC) is ranked the fourth most prevalent cancer and the second leading cause of cancer death. GC is often discovered late when the majority of patients are ineligible for treatment. The existing systemic chemotherapy exhibits low efficiency with low survival rate. The present study reviewed new insights into therapeutic agents, various alternative strategies for treatment, such as neoadjuvant and adjuvant therapy, nanotherapy, and natural medicines. Moreover, it points out to current surgical techniques such as endoscopic and laparoscopic resection as well as findings in pathophysiology, epidemiology, risk factors, diagnosis, prevention, and screening approaches in GC.

Commentary 

The article points out to important strategic therapeutic plan in a multidisciplinary team between endoscopists, oncologists, surgeon and pathologists. The neoadjuvant therapy strategy makes careful assessment of endoscopic, radiologic and pathology staging paramount for proper treatment selection. Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR), and Submucosal Tunnel Endoscopic Resection (STER) are super minimally invasive procedures that need careful patient selection and assessment. Endoscopic Ultrasonography may also help in assessment. More data is needed to determine cost-effective analysis of validated screening program and updates on risk factors and epidemiology.

Citation

Authors: Azadbakht, Saleh; Baharvand, Parastoo; Saki, Mojgan; Moayyedkazemi, Alireza

Source: Current Cancer Therapy Reviews, Volume 19, Number 1, 2023, pp. 19-36(18)

DOI: https://doi.org/10.2174/1573394718666220428105301

View past News You Can Use commentaries